ES2165505T3 - Compuestos aromaticos y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos aromaticos y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2165505T3
ES2165505T3 ES96920936T ES96920936T ES2165505T3 ES 2165505 T3 ES2165505 T3 ES 2165505T3 ES 96920936 T ES96920936 T ES 96920936T ES 96920936 T ES96920936 T ES 96920936T ES 2165505 T3 ES2165505 T3 ES 2165505T3
Authority
ES
Spain
Prior art keywords
sup
sub
rent
optionally replaced
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920936T
Other languages
English (en)
Inventor
Gloria Anne Breault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9512476.4A external-priority patent/GB9512476D0/en
Priority claimed from GBGB9601462.6A external-priority patent/GB9601462D0/en
Priority claimed from GBGB9606831.7A external-priority patent/GB9606831D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2165505T3 publication Critical patent/ES2165505T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) EN LOS QUE A ES UN SISTEMA DE ANILLO OPCIONALMENTE SUSTITUIDO, CON LA CONDICION DE QUE LOS GRUPOS -CH(R SUP,3})N(R SUP,2})B-R SUP,1} Y -OR SUP,4} ESTAN COLOCADOS EN UNA RELACION 1,2 UNO RESPECTO AL OTRO EN ATOMOS DE CARBONO DEL ANILLO, Y EL ATOMO DEL ANILLO COLOCADO EN POSICION ORTO RESPECTO AL GRUPO DE UNION -OR SUP,4} (Y POR CONSIGUIENTE EN LA POSICION 3 EN RELACION CON EL GRUPO DE UNION -CHR SUP,3}NR SUP,2}-) NO ESTA SUSTITUIDO; B ES UN SISTEMA DE ANILLO OPCIONALMENTE SUSTITUIDO; R SUP,1} ESTA POSICIONADO EN EL ANILLO B EN UNA RELACION 1,3 O 1,4 CON EL GRUPO DE UNION CHR SUP,3}NR SUP,2}-, Y ES COMO SE DEFINE EN LA ESPECIFICACION, R SUP,2} ES HIDROGENO, ALQUILO C SUB,1-6}, OPCIONALMENTE SUSTITUIDO CON HIDROXI, CIANO O TRIFLUOROMETILO, ALQUENILO C SUB,2-6} (CON LA CONDICION DE QUE EL DOBLE ENLACE NO ESTA EN LA POSICION 1), ALQUINILO C SUB,2-6} (CON LA CONDICION DE QUE EL TRIPLE ENLACE NO ESTA EN LA POSICION 1), FENILALQUILO C SUB,1-3} O PIRIDILALQUILO C SUB,1-3}; R SUP,3} ES HIDROGENO, METILO O ETILO; R SUP,4} ESTA OPCIONALMENTE SUSTITUIDO: ALQUILO C SUB,16}, CICLOALQUILC SUB,3-7}ALQUILC SUB,1-3} O CICLOALQUILC SUB,37}; Y N - OXIDOS DE -NR SUP,2} CUANDO SON QUIMICAMENTE POSIBLES; Y S - OXIDOS DE AZUFRE QUE CONTIENEN ANILLOS CUANDO ES QUIMICAMENTE POSIBLE; Y SALES FARMACEUTICAMENTE ACEPTABLES Y ESTERES Y AMIDAS HIDROLIZABLES IN VIVO DE LOS MISMOS. PROCESOS PARA SU PREPARACION, SU USO COMO AGENTES TERAPEUTICOS Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES96920936T 1995-06-20 1996-06-17 Compuestos aromaticos y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2165505T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9512476.4A GB9512476D0 (en) 1995-06-20 1995-06-20 Aromatic compounds
GBGB9601462.6A GB9601462D0 (en) 1996-01-25 1996-01-25 Aromatic compounds
GBGB9606831.7A GB9606831D0 (en) 1996-03-30 1996-03-30 Aromatic compounds

Publications (1)

Publication Number Publication Date
ES2165505T3 true ES2165505T3 (es) 2002-03-16

Family

ID=27267781

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920936T Expired - Lifetime ES2165505T3 (es) 1995-06-20 1996-06-17 Compuestos aromaticos y composiciones farmaceuticas que los contienen.

Country Status (29)

Country Link
US (2) US5994353A (es)
EP (1) EP0835246B1 (es)
JP (1) JP3949166B2 (es)
KR (1) KR19990023006A (es)
CN (1) CN1193963A (es)
AR (1) AR004495A1 (es)
AT (1) ATE207468T1 (es)
AU (1) AU700337B2 (es)
BG (1) BG63777B1 (es)
BR (1) BR9608956A (es)
CA (1) CA2220925A1 (es)
CZ (1) CZ290923B6 (es)
DE (1) DE69616323T2 (es)
DK (1) DK0835246T3 (es)
EE (1) EE9700341A (es)
ES (1) ES2165505T3 (es)
HR (1) HRP960288B1 (es)
HU (1) HUP9802317A3 (es)
IL (1) IL118664A (es)
MX (1) MX9710218A (es)
MY (1) MY116531A (es)
NO (1) NO311129B1 (es)
NZ (1) NZ311082A (es)
PL (1) PL324205A1 (es)
PT (1) PT835246E (es)
RO (1) RO119945B1 (es)
SK (1) SK282450B6 (es)
TW (1) TW434240B (es)
WO (1) WO1997000863A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
EP0752421B1 (en) 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
US6242474B1 (en) 1997-06-27 2001-06-05 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
WO2002072145A1 (fr) * 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
ES2305310T3 (es) 2001-10-23 2008-11-01 Laboratoires Serono Sa Compuestos de pirazolidinona como ligandos de los receptores de ep2 y/o ep4 de prostaglandinas.
WO2003043655A1 (fr) * 2001-11-19 2003-05-30 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
ES2337887T3 (es) 2001-12-20 2010-04-30 Merck Serono Sa Derivados de pirrolidina en calidad de moduladores de prostaglandina.
JP4754820B2 (ja) 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
EP1824819B1 (en) 2004-12-06 2010-01-20 Merck Serono SA Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
US20100137378A1 (en) 2004-12-23 2010-06-03 Glaxo Group Limited Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
CN101663034B (zh) 2007-02-16 2014-11-05 小野药品工业株式会社 用于排尿障碍的治疗剂
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
JP6242810B2 (ja) 2011-12-28 2017-12-06 グローバル・ブラッド・セラピューティクス・インコーポレイテッドGlobal Blood Therapeutics,Inc. 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903220C (en) 2013-03-15 2023-01-24 Qing Xu Aldehyde compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MX2015011448A (es) 2013-03-15 2016-06-06 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) * 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657430A (en) * 1969-06-25 1972-04-18 Merck & Co Inc Composition and methods for treating inflammation
US3632760A (en) * 1969-06-25 1972-01-04 Merck & Co Inc Treatment of inflammation
US4350822A (en) * 1975-03-12 1982-09-21 American Cyanamid Company Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives
AU510758B2 (en) * 1976-01-19 1980-07-10 The Dow Chemical Company P-benzylaminobenzoic acids
US4206145A (en) * 1976-02-11 1980-06-03 Beecham Group Limited Hypolipidaemic compounds and compositions
GB1576007A (en) * 1976-02-11 1980-10-01 Beecham Group Ltd Hypolipidaemic compositions
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
US4152452A (en) * 1977-10-06 1979-05-01 William H. Rorer, Inc. Method of topically treating inflammation
DK531479A (da) * 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
US4277496A (en) * 1979-06-04 1981-07-07 Laboratorios Bago S.A. Methods of treating mammals suffering from inflammation and pain
US4578390A (en) * 1981-12-14 1986-03-25 Merck & Co., Inc. Hydroxybenzylamino derivatives as anti-inflammatory agents
CA1193598A (en) * 1982-05-06 1985-09-17 Rafael Foguet 2-amino-benzoic acid derivatives and processes for their production
IE56702B1 (en) * 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB8320699D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Ethylenediamines
US4614617A (en) * 1985-02-25 1986-09-30 G. D. Searle & Co. Intermediates for 8-chlorodibenz[(b,f)][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides
US4559336A (en) * 1985-02-25 1985-12-17 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4937373A (en) * 1988-12-08 1990-06-26 Hoffmann-La Roche Inc. Substituted naphthalene carboxylic acids
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
UA27031A1 (uk) * 1990-04-25 2000-02-28 Ніссан Кемікал Індастріз Лтд Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові
IE912956A1 (en) * 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
US5284954A (en) * 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
US5250548A (en) * 1990-09-10 1993-10-05 Abbott Laboratories Angiotensin II receptor antagonists
US5210206A (en) * 1990-09-10 1993-05-11 Abbott Laboratories 1,3-oxazolyl substituted biphenyl
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9120640D0 (en) * 1991-09-27 1991-11-06 Ici Plc Tricyclic heterocycles
JPH05230016A (ja) * 1991-10-14 1993-09-07 Takeda Chem Ind Ltd アミド誘導体、その製造法および殺菌剤
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5441950A (en) * 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US5530157A (en) * 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
TW454123B (en) 1999-01-28 2001-09-11 Ibm Method and system for enabling pervasive computing devices to communicate with each other

Also Published As

Publication number Publication date
HRP960288B1 (en) 2003-02-28
AU6232096A (en) 1997-01-22
RO119945B1 (ro) 2005-06-30
NO975985L (no) 1997-12-19
CN1193963A (zh) 1998-09-23
HUP9802317A2 (hu) 1999-03-29
US6365603B1 (en) 2002-04-02
DE69616323T2 (de) 2002-07-25
HRP960288A2 (en) 1998-02-28
BG102173A (en) 1998-09-30
NZ311082A (en) 2000-01-28
CZ290923B6 (cs) 2002-11-13
EP0835246A1 (en) 1998-04-15
EP0835246B1 (en) 2001-10-24
AR004495A1 (es) 1998-12-16
CZ410997A3 (cs) 1998-03-18
JPH11508878A (ja) 1999-08-03
EE9700341A (et) 1998-06-15
CA2220925A1 (en) 1997-01-09
TW434240B (en) 2001-05-16
KR19990023006A (ko) 1999-03-25
IL118664A (en) 2001-12-23
BR9608956A (pt) 1999-03-02
IL118664A0 (en) 1996-10-31
JP3949166B2 (ja) 2007-07-25
SK173297A3 (en) 1998-07-08
NO311129B1 (no) 2001-10-15
US5994353A (en) 1999-11-30
SK282450B6 (sk) 2002-02-05
NO975985D0 (no) 1997-12-19
AU700337B2 (en) 1998-12-24
BG63777B1 (bg) 2002-12-29
HUP9802317A3 (en) 2001-11-28
DE69616323D1 (de) 2001-11-29
MY116531A (en) 2004-02-28
PL324205A1 (en) 1998-05-11
DK0835246T3 (da) 2002-01-21
MX9710218A (es) 1998-03-31
WO1997000863A1 (en) 1997-01-09
PT835246E (pt) 2002-04-29
ATE207468T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
ES2165505T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
ES2169248T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
PA8503601A1 (es) Derivados de purina
ES2140391T3 (es) Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ES2174629T3 (es) 14,15-ciclopropano-esteroides de la serie de los 19-nor-androstanos, procedimiento para su preparacion y formulaciones farmaceuticas que contienen estos compuestos.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ES2093753T3 (es) Derivados de estireno.
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
DOP2001000195A (es) Derivados de purina
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ES2145379T3 (es) Uso de dioxabiciclo(3.3.0)octanos para el tratamiento y la prevencion de la apoplejia cerebral.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
CO4940430A1 (es) Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
ES2184989T3 (es) Derivados de feniletanolaminotetralincarboxamida 3,4-disustituidos.
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
ES2139965T3 (es) Benzoilguanidinas sustituidas con grupos de caracter basico, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 835246

Country of ref document: ES